Vir Biotechnology Announces Pricing of Public Offering of Common Stock - November 12, 2026
Vir Biotechnology (VIR) priced a public offering of 15M shares at $10 each, raising $150M. It granted underwriters a 30-day option for additional 2.25M shares. Closing is expected Nov 16, 2026. Leerink, Morgan Stanley, and Evercore ISI are bookrunners. The offering was filed with the SEC.
How this was made

The 30-second read
Why it matters
The $150 M raise adds cash to the balance sheet but introduces dilution; investors will watch how the capital is allocated.
Market read
Primary disclosure of a sizable secondary offering; short‑term price impact expected, with longer‑term implications tied to capital deployment.
What to watch
Potential strategic partnership or pipeline milestone that could be funded by the capital raise.
Background
Vir Biotechnology is a clinical‑stage biopharma focused on infectious diseases and oncology, with a pipeline that includes hepatitis delta and PRO‑XTEN® T‑cell engagers.
Ticker impact
Vir Biotechnology announced pricing of a $150 million public offering of 15 M shares at $10 each, with a 30‑day over‑allotment option.
likely downward pressure as the market prices in dilution from the $150 M raise
New capital raise of significant size (>$100 M) is a primary disclosure; dilution typically depresses price until proceeds are deployed.
Market effects
Biotech sector may see modest sell‑off as investors reassess dilution risk across similar small‑cap pipelines.
US biotech market may experience slight negative bias in the short term.
Limited to investors tracking US‑listed biotech offerings.
Counterpoint
If the proceeds fund high‑impact trials, the long‑term upside could outweigh short‑term dilution.
Key entities
- companyVir Biotechnology, Inc.
Issuer of the public offering.
- financial_institutionLeerink Partners, Morgan Stanley, Evercore ISI
Book‑running managers for the offering.


